Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Betamethasone Dipropionate; Calcipotriene Patent Expiration

Betamethasone Dipropionate; Calcipotriene is used for treating schizophrenia, bipolar disorder, and major depressive disorder. It was first introduced by Leo Pharma As in its drug Taclonex on Jan 9, 2006. Other drugs containing Betamethasone Dipropionate; Calcipotriene are Wynzora, Enstilar. 7 different companies have introduced drugs containing Betamethasone Dipropionate; Calcipotriene.


Betamethasone Dipropionate; Calcipotriene Patents

Given below is the list of patents protecting Betamethasone Dipropionate; Calcipotriene, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Wynzora US11638711 NULL Mar 18, 2039 Mc2
Wynzora US11696919 Topical composition Mar 18, 2039 Mc2
Enstilar US10130640

(Pediatric)

 Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Dec 10, 2031 Leo Pharma As
Enstilar US9119781

(Pediatric)

 Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Dec 10, 2031 Leo Pharma As
Enstilar US10130640 Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Jun 10, 2031 Leo Pharma As
Enstilar US10617698 Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid Jun 10, 2031 Leo Pharma As
Enstilar US10660908 Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Jun 10, 2031 Leo Pharma As
Enstilar US10682364 Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid Jun 10, 2031 Leo Pharma As
Enstilar US10688108 Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Jun 10, 2031 Leo Pharma As
Enstilar US10716799 Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Jun 10, 2031 Leo Pharma As
Enstilar US9119781 Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Jun 10, 2031 Leo Pharma As
Enstilar US9566286 Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Jun 10, 2031 Leo Pharma As
Wynzora US10265265 Topical composition Sep 27, 2027 Mc2
Enstilar US6753013 Pharmaceutical composition Jan 27, 2020

(Expired)

 Leo Pharma As
Taclonex US6753013 Pharmaceutical composition Jan 27, 2020

(Expired)

 Leo Pharma As
Taclonex US6787529 Topical composition Jan 27, 2020

(Expired)

 Leo Pharma As
Taclonex US5763426 Crystalline form of a vitamin D analogue Jun 09, 2015

(Expired)

 Leo Pharma As
Taclonex USRE39706 Crystalline form of a vitamin D analogue Jun 09, 2015

(Expired)

 Leo Pharma As



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Betamethasone Dipropionate; Calcipotriene's patents.

Given below is the list recent legal activities going on the following patents of Betamethasone Dipropionate; Calcipotriene.

Activity Date Patent Number
Patent litigations
Patent eCofC Notification 19 Mar, 2024 US11696919
Mail Patent eCofC Notification 19 Mar, 2024 US11638711
Mail Patent eCofC Notification 19 Mar, 2024 US11696919
Patent eCofC Notification 19 Mar, 2024 US11638711
Email Notification
Critical
 19 Mar, 2024 US11696919
Recordation of Patent eCertificate of Correction 19 Mar, 2024 US11696919
Email Notification
Critical
 19 Mar, 2024 US11638711
Recordation of Patent eCertificate of Correction 19 Mar, 2024 US11638711
Mail Certificate of Correction Memo 28 Feb, 2024 US11696919
Mail Certificate of Correction Memo 28 Feb, 2024 US11638711


Betamethasone Dipropionate; Calcipotriene's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Betamethasone Dipropionate; Calcipotriene Generic API Manufacturers

Several generic applications have been filed for Betamethasone Dipropionate; Calcipotriene. The first generic version for Betamethasone Dipropionate; Calcipotriene was by Chartwell Rx Sciences Llc and was approved on Jan 14, 2013. And the latest generic version is by Glenmark Pharmaceuticals Ltd and was approved on Mar 21, 2023.

Given below is the list of companies who have filed for Betamethasone Dipropionate; Calcipotriene generic, along with the locations of their manufacturing plants worldwide.


1. CHARTWELL RX

Chartwell Rx Sciences Llc has filed for 1 generic for Betamethasone Dipropionate; Calcipotriene. This 0.064%;0.005% version comes by the name CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE. Given below are the details of the strengths of this generic introduced by Chartwell Rx.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.064%; 0.005%

ointment Discontinued TOPICAL N/A Jan 14, 2013





2. COSETTE

Cosette Pharmaceuticals Inc has filed for 1 generic for Betamethasone Dipropionate; Calcipotriene. This 0.064%;0.005% version comes by the name CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE. Given below are the details of the strengths of this generic introduced by Cosette.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.064%; 0.005%

suspension Prescription TOPICAL AB May 11, 2020


Manufacturing Plant Locations
New

Cosette's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Cosette as present at those locations.

Country City Firm Name
United States
Lincolnton Cosette Pharmaceuticals NC Laboratories, LLC
South Plainfield Cosette Pharmaceuticals, Inc.





3. GLENMARK PHARMS LTD

Glenmark Pharmaceuticals Ltd has filed for 1 generic for Betamethasone Dipropionate; Calcipotriene. This 0.064%;0.005% version comes by the name CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE. Given below are the details of the strengths of this generic introduced by Glenmark Pharms Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.064%; 0.005%

aerosol, foam Prescription TOPICAL AB Mar 21, 2023





4. PADAGIS ISRAEL

Padagis Israel Pharmaceuticals Ltd has filed for 1 generic for Betamethasone Dipropionate; Calcipotriene. This 0.064%;0.005% version comes by the name CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE. Given below are the details of the strengths of this generic introduced by Padagis Israel.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.064%; 0.005%

suspension Prescription TOPICAL AB Sep 11, 2020


Manufacturing Plant Locations
New

Padagis Israel's manufacturing plants are situated in 1 country - Israel. Given below are the details of these plant locations as well as the firm names of Padagis Israel as present at those locations.

Country City Firm Name
Israel
Yerucham Padagis Israel Pharmaceuticals Ltd.





5. TARO

Taro Pharmaceuticals Inc has filed for 1 generic for Betamethasone Dipropionate; Calcipotriene. This 0.064%;0.005% version comes by the name CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE. Given below are the details of the strengths of this generic introduced by Taro.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.064%; 0.005%

suspension Prescription TOPICAL AB Sep 2, 2020


Manufacturing Plant Locations
New

Taro's manufacturing plants are situated in 3 countries - United States, Israel, Canada. Given below are the details of these plant locations as well as the firm names of Taro as present at those locations.

Country City Firm Name
United States
Hawthorne Taro Pharmaceuticals U.S.A., Inc.
Honolulu Taro Delight, LLC
Israel
Haifa Taro Pharmaceutical Industries, Ltd.
Canada
Brampton Taro Pharmaceuticals Inc.